EQUITY RESEARCH - ANALYST MEETING

PRARAM 9 HOSPITAL

THAILAND / HEALTH CARE SERVICES

PR9 TB



FSSIA ESG rating





TARGET PRICE	THB22.00
CLOSE	THB14.00
UP/DOWNSIDE	+57.1%
TP vs CONSENSUS	+1.9%

Highlights

- We have positive feedback from the 3Q23 analyst meeting.
- Management expects strong revenue growth both q-q and y-y in 4Q23 with an improving margin, as fixed costs have been stable since 3Q23. They target revenue growth of 3-4% in 2023, implying THB1.2b in revenue in 4Q23 (vs THB1.07b in 3Q23).

Key takeaways from analyst meeting

- In addition, management targets revenue growth of 10% in 2024 with an improving net profit margin.
- Kidney transplant cases hit a new record high at 88 cases (as of mid-Nov) vs 86 cases in 2023.
- Expect strong growth of 20% y-y from international patient revenue, with the international revenue contribution rising from 14% to 16% in 2024, driven by patients from CLMV, China and the Middle East.
- PR9 recently set up a new international marketing team to contact more agencies to refer Middle East patients. Full operations are likely to start in 1Q24.
- PR9 is in the process of renovating around 24 ICU and CCU beds in 4Q23. This should increase the number of operating beds from 180 to 204 beds by the end of this year. The hospital also plans to add 20 more IPD beds in 2024.
- PR9 is considering increasing service fees after the completion of renovations on building A, probably in 2024.

Recommendation

PR9's share price has plunged by 17% over the past month amid the weak market, providing an opportunity to Buy the stock, premised on 1) the upward trend of IPD patient bed-days in 4Q23; 2) earnings growth q-q and y-y in 4Q23, with the scope of a new record high; and 3) potential new S-Curve growth from Middle East patients. PR9 also trades at a cheap valuation of only 18x 2024E P/E.

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	4,107	4,153	4,491	4,765
Net profit	568	506	603	655
EPS (THB)	0.72	0.64	0.77	0.83
vs Consensus (%)	-	0.9	8.8	3.4
EBITDA	991	927	1,062	1,143
Recurring net profit	568	506	603	655
Core EPS (THB)	0.72	0.64	0.77	0.83
EPS growth (%)	127.8	(10.9)	19.2	8.7
Core P/E (x)	19.4	21.8	18.3	16.8
Dividend yield (%)	2.1	2.3	2.7	3.0
EV/EBITDA (x)	9.4	9.8	8.2	7.2
Price/book (x)	2.3	2.2	2.1	1.9
Net debt/Equity (%)	(36.1)	(38.8)	(43.6)	(47.7)
ROE (%)	12.6	10.4	11.6	11.8




Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(16.7)	(22.7)	(20.9)
Relative to country (%)	(14.6)	(16.9)	(8.9)
Mkt cap (USD m)			311
3m avg. daily turnover (US	D m)		0.7
Free float (%)			59
Major shareholder	Khunying Potja	aman Damap	ong (37%)
12m high/low (THB)		2	1.30/13.10
Issued shares (m)			786.30

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: Non-Covid Thai patient revenue




Sources: PR9; FSSIA estimates

Exhibit 3: EBITDA margin




Sources: PR9; FSSIA estimates

Exhibit 5: IPD average daily census (ADC)




Sources: PR9; FSSIA estimates

Exhibit 2: International patient revenue



Sources: PR9; FSSIA estimates

Exhibit 4: Core profit



Sources: PR9; FSSIA estimates

Exhibit 6: Middle East International marketing team



Sources: PR9; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	2,987	4,107	4,153	4,491	4,765
Cost of goods sold	(2,172)	(2,724)	(2,789)	(2,985)	(3,156)
Gross profit	815	1,384	1,364	1,507	1,609
Other operating income	39	43	46	60	62
Operating costs	(557)	(735)	(789)	(826)	(867)
Operating EBITDA	590	991	927	1,062	1,143
Depreciation	(294)	(299)	(306)	(321)	(340)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	297	692	621	741	803
Net financing costs	4	8	12	13	16
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	300	700	632	754	819
Гах	(51)	(132)	(126)	(151)	(164)
Profit after tax	249	568	506	603	655
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	249	568	506	603	655
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	249	568	506	603	655
Per share (THB)					
Recurring EPS *	0.32	0.72	0.64	0.77	0.83
Reported EPS	0.32	0.72	0.64	0.77	0.83
DPS .	0.14	0.29	0.32	0.38	0.42
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	14.8	37.5	1.1	8.2	6.1
Operating EBITDA (%)	33.0	67.9	(6.5)	14.6	7.7
Operating EBIT (%)	28.5	133.3	(10.3)	19.3	8.5
Recurring EPS (%)	23.3	127.8	(10.9)	19.2	8.7
Reported EPS (%)	23.3	127.8	(10.9)	19.2	8.7
Operating performance					
Gross margin inc. depreciation (%)	27.3	33.7	32.8	33.6	33.8
Gross margin exc. depreciation (%)	37.1	41.0	40.2	40.7	40.9
Operating EBITDA margin (%)	19.8	24.1	22.3	23.6	24.0
Operating EBIT margin (%)	9.9	16.8	14.9	16.5	16.9
Net margin (%)	8.3	13.8	12.2	13.4	13.8
Effective tax rate (%)	17.0	18.9	20.0	20.0	20.0
Dividend payout on recurring profit (%)	44.2	40.2	50.0	50.0	50.0
Interest cover (X)	(79.4)	(84.0)	(54.0)	(56.3)	(50.5)
nventory days	10.2	8.1	7.6	7.5	7.5
Debtor days	22.7	20.2	22.7	22.3	21.0
Creditor days	101.4	82.5	74.3	72.6	73.1
Operating ROIC (%)	7.7	18.1	16.4	19.5	21.4
ROIC (%)	7.5	17.4	15.3	18.2	20.0
ROE (%)	5.9	12.6	10.4	11.6	11.8
ROA (%)	5.0	10.5	8.7	9.8	10.0
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
OPD patient revenue	1,620	2,383	2,376	2,570	2,726
PD patient revenue	1,367	1,725	1,777	1,922	2,039

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025
Recurring net profit	249	568	506	603	65
Depreciation	294	299	306	321	34
Associates & minorities Other non-cash items	3	10	0	0	
Change in working capital	27	(5)	(19)	41	3
Cash flow from operations	574	871	793	965	1,03
Capex - maintenance	(235)	(140)	(328)	(320)	(339
Capex - new investment	· -	-	-	-	
Net acquisitions & disposals	0	(150)	0	0	
Other investments (net)	-	-	-	-	
Cash flow from investing	(235)	(290)	(328)	(320)	(339
Dividends paid	(86)	(110)	(228)	(253)	(301
Equity finance	0	0 2	0	0	
Debt finance Other financing cash flows	(2) 0	0	0	0	
Cash flow from financing	(88)	(108)	(228)	(253)	(301
Non-recurring cash flows	-	-	-	-	(55)
Other adjustments	0	0	0	0	
Net other adjustments	0	0	0	0	(
Movement in cash	250	473	237	393	39
Free cash flow to firm (FCFF)	338.71	581.44	465.46	646.06	691.5
ree cash flow to equity (FCFE)	336.58	582.47	464.92	645.53	691.0
Per share (THB)					
FCFF per share	0.43	0.74	0.59	0.82	0.8
FCFE per share	0.43	0.74	0.59	0.82	0.8
Recurring cash flow per share	0.69	1.11	1.03	1.18	1.2
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025
Fangible fixed assets (gross)	5,565	5,638	5,965	6,285	6,62
Less: Accumulated depreciation	(2,090)	(2,322)	(2,628)	(2,949)	(3,289
Tangible fixed assets (net)	3,475	3,315	3,337	3,336	3,33
ntangible fixed assets (net)	0	0	0	0	.,
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	4	154	154	154	15
Cash & equivalents	1,244	1,717	1,954	2,347	2,73
A/C receivable	212	243	274	274	27
nventories	56	51	53	56	6
Other current assets	90	12	12	13	1
Current assets	1,603	2,023	2,293	2,690	3,08
Other assets Fotal assets	55 5,137	65 5,558	65 5,849	65 6,245	6, 63
Common equity	4,278	4,735	5,013	5,363	5,71
Minorities etc.	0	0	0,010	0,000	0,7 1
Fotal shareholders' equity	4,278	4,735	5,013	5,363	5,71
Long term debt	6	8	8	8	,
Other long-term liabilities	190	209	209	209	20
ong-term liabilities	196	217	217	217	21
A/C payable	597	499	512	549	58
Short term debt	0	0	0	0	
Other current liabilities	66	106	107	116	12
Current liabilities	663	606	619	665	70
Total liabilities and shareholders' equity	5,137	5,558	5,849	6,245	6,63
Net working capital	(305)	(299)	(280)	(321)	(35) 3,19
nvested capital Includes convertibles and preferred stock which is bei	3,230	3,235	3,276	3,233	3, 18
<u> </u>	ng troutou do dobt				
Per share (THB)		2.65	2.55	0.00	_
Book value per share	5.44	6.02	6.38	6.82	7.2
Fangible book value per share	5.44	6.02	6.38	6.82	7.2
Financial strength	(20.0)	(20.4)	(20.0)	(42.0)	/47
Net debt/equity (%)	(28.9)	(36.1)	(38.8)	(43.6)	(47.
Net debt/total assets (%) Current ratio (x)	(24.1) 2.4	(30.8)	(33.3) 3.7	(37.5) 4.0	(41. 4
CF interest cover (x)	(89.2)	(69.7)	(39.4)	(48.0)	(42.
/aluation	2021	2022	2023E	2024E	2025
Recurring P/E (x) *	44.2	19.4	21.8	18.3	16
Recurring P/E @ target price (x) *	69.4	30.5	34.2	28.7	26
Reported P/E (x)	44.2	19.4	21.8	18.3	16
Dividend yield (%)	1.0	2.1	2.3	2.7	3
Price/book (x) Price/tangible book (x)	2.6 2.6	2.3 2.3	2.2 2.2	2.1 2.1	1
EV/EBITDA (x) **	2.6 16.6	2.3 9.4	2.2 9.8	2.1 8.2	1 7
EV/EBITDA (x) EV/EBITDA @ target price (x) **	27.2	9.4 15.7	9.6 16.6	0.2 14.1	12
EV/invested capital (x)	3.0	2.9	2.8	2.7	2

Sources: Praram 9 Hospital; FSSIA estimates

Praram 9 Hospital PCL (PR9 TB)



Exhibit 7: FSSIA ESG score implication

54.08 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA		Domestic ratings						Global ratings					Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
всн	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
вн	51.21			-	4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25			-	4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00			-	4.00	4.00	Certified								
RAM	11.75			-	3.00			High							
THG	18.75			-	5.00	5.00		High							
VIBHA	20.88			-	4.00	3.00	Declared	High					17.00	-	

 $Sources: \underline{\textbf{SETTRADE.com}}; \ \textbf{FSSIA's compilation}$

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	_	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	_	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	0
GHG scope 2 location-based	_	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	_	_	_
Electricity used	_	_	_
Fuel used - natural gas	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	_	_	_
Total waste	_	_	_
Waste recycled	_	_	_
Waste sent to landfills	_	_	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption	_	60	151
Social			
Human rights policy	Yes	Yes	Ye
Policy against child labor	No	Yes	Ye
Quality assurance and recall policy	No	Yes	Ye
Consumer data protection policy	No	Yes	Ye
Equal opportunity policy	Yes	Yes	Ye
Gender pay gap breakout	No	No	N
Pct women in workforce	_	_	-
Pct disabled in workforce	_	_	_
Business ethics policy	No	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Ye
Health and safety policy	No	Yes	Ye
Lost time incident rate - employees	_	_	_
Total recordable incident rate - employees	_	1	(
Training policy	Yes	Yes	Ye
Fair remuneration policy	No	No	N
Number of employees – CSR	2,083	1,987	2,01
Employee turnover pct	_	11	1:
Total hours spent by firm - employee training	14,566	13,462	66,85
Social supply chain management	No	No	No
Governance			
Board size	10	10	!
No. of independent directors (ID)	4	7	
No. of women on board	2	2	
No. of non-executive directors on board	7	7	
Company conducts board evaluations	Yes	Yes	Ye
No. of board meetings for the year	7	7	
Board meeting attendance pct	97	100	8
Board duration (years)	3	3	
Director share ownership guidelines	No	No	N
Age of the youngest director	56	56	5
Age of the oldest director	72	73	7
No. of executives / company managers	7	5	
No. of female executives	2	0	
Executive share ownership guidelines	No	No	N
Size of audit committee	3	3	
No. of ID on audit committee	3	3	
Audit committee meetings	4	4	
Audit meeting attendance %	100	100	10
Size of compensation committee	3	3	
No. of ID on compensation committee	3	2	
No. of compensation committee meetings	2	2	
Compensation meeting attendance %	83	100	10
Size of nomination committee	3	3	
No. of nomination committee meetings	2	2	
Nomination meeting attendance %	83	100	10
Sustainability governance			
Verification type	No	No	N

 $Sources: Bloomberg; FSSIA's \ compilation$

Disclaimer for ESG scoring

	or Loc occurring									
ESG score	Methodology			Rating						
The Dow Jones Sustainability ndices (<u>DJSI</u>) By S&P Global	process based on the from the annual S&P	es a transparent, rules-based companies' Total Sustainabil Global Corporate Sustainabili companies within each industr	ity Scores resulting ty Assessment (CSA).	ESG Score of	Assessment less than 45 iny are disqu	(CSA) for DJS % of the S&P of the co	I. Companie: Global ESG :	orporate s with an S&P (Score of the hig the DJSI indice	ghest	
Sustainability nvestment List (THSI) by The Stock Exchange of Thailand (SET)	managing business w Candidates must pass 1) no irregular trading float of >150 sharehol up capital. Some key 70%; 2) independent wrongdoing related to	onsibility in Environmental and yith transparency in Governand is the preemptive criteria, with of the board members and exiders, and combined holding in disqualifying criteria include: " directors and free float violatic of CG, social & environmental in displayments of the combined of the comb	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	nature of the relevant industry and materiality.				nst th rket dity SI		
oy Thai nstitute of Directors Association Thai IOD)	annually by the Thai I	rength in sustainable developr OD, with support from the Sto results are from the perspectiv ations.	ock Exchange of	Good (80-89), and not rated t equitable treat	3 for Good (for scores be ment of shar 25%); 4) disc	(70-79), 2 for F elow 50. Weigh reholders (weig	air (60-69), 1 tings include _I ht 25% com	100), 4 for Very for Pass (60-6 : 1) the rights; 2 bined); 3) the ro %); and 5) boar	59), 2) an ole o	
AGM level By Thai nvestors Association (TIA) with support from the SEC	treatment are incorpor transparent and suffic out of five the CG con assessment criteria cu the meeting date (45% advance circulation of suf- rights can be exercised. I transparency and verifiab	t to which shareholders' rights rated into business operations ciently disclosed. All form import more AGM procedures before 1/9, and after the meeting (10) fficient information for voting; and 2 The second assesses 1) the ease of initity; and 3) openness for Q&A. Thuld contain discussion issues, rescuit	s and information is ortant elements of two ually. The the meeting (45%), at %). (The first assesses 1) 2) facilitating how voting of attending meetings; 2) e third involves the					cellent (100), 4 ir scores below		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishment of key of policies. The Certifica (Companies deciding to be Declaration of Intent to kin Certification, including risi	the Checklist include corruptic controls, and the monitoring a tion is good for three years. become a CAC certified member st ck off an 18-month deadline to sub k assessment, in place of policy ar s, establishment of whistleblowing s to all stakeholders.)	and developing of tart by submitting a mit the CAC Checklist for and control, training of	passed Checklist will move for granting certification by the CAC Cour approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					ncil	
Morningstar Sustainalytics	based on an assessm risk is unmanaged. So	SG risk rating provides an ove nent of how much of a compar ources to be reviewed include corp	ny's exposure to ESG orate publications and	A company's E more risk is un				anaged risk. Th d.	те	
		nd other media, NGO reports/webs edback, ESG controversies, issuer er reviews.		NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+		
ESG Book	positioned to outperfo the principle of financi helps explain future ris	fies sustainable companies th orm over the long term. The mial materiality including inform isk-adjusted performance. Mates with higher materiality and uarterly basis.	ethodology considers ation that significantly teriality is applied by		nateriality-ba		he score is s	caled between		
<u>MSCI</u>		m to measure a company's ma ers and laggards according to							gy to	
	AAA 8.571-1	Leader:	leading its industry in n	nanaging the most s	significant ESC	risks and opport	unities			
	AA 7.143- A 5.714-									
	BBB 4.286-		a mixed or unexception	nal track record of m	anaging the n	nost significant ES	G risks and o	portunities relativ	ve to	
	BB 2.857-	<u> </u>	industry peers							
	B 1.429-		lagging its industry bas	ad on its high over	sure and fail	e to manage ei	ificant ESC =i=	ke		
	CCC 0.000-	Laggard: -1.428	lagging its industry bas	eu on its riign expo	oure and IailUf	e to manage sign	incani eog fis	NO .		
Moody's ESG solutions	believes that a compa	e degree to which companies any integrating ESG factors in lue for shareholders over the	to its business model an							
Refinitiv ESG rating	based on publicly ava	ently and objectively measure iilable and auditable data. The G data publicly. (<i>Score ratings</i> a	e score ranges from 0 to	100 on relative E	SG perform	nance and insu	fficient degre			
S&P Global		Score is a relative score meas within the same industry clas				nt of ESG risks	s, opportuniti	es, and impacts	s	
Bloomberg	ESG Score	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.								
		of Pillar Scores, where	the weights are determin	ned by the pillar p	oriority ranki	ng. Values ranç	ge from 0 to	10; 10 is the be	est.	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
20-Nov-2020 26-Apr-2021 16-Jul-2021	BUY BUY BUY	12.00 13.00 14.00	10-Jan-2022 22-Apr-2022 12-Jul-2022	BUY BUY BUY	15.00 16.50 18.00	11-Oct-2022 17-Jan-2023	BUY BUY	21.00 22.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 14.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 15-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.